Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17319105 | 0.98 | NEK2 (0.33) | NEK2GAACRBNSLC6A2SLC6A4 | |
| Bromide SCHEMBL6621805 | 0.98 | NEK2 (0.33) | NEK2GAACRBNSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL17319015 | 0.98 | NEK2 (0.33) | NEK2GAACRBNSLC6A2SLC6A4 | |
| SCHEMBL1382655 | 0.90 | CRBN (0.35) | GAACRBN | |
| SCHEMBL24246661 | 0.87 | — | — | |
| SCHEMBL22259418 | 0.83 | SLC6A2 (0.33) | GAASLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL22449836 | 0.83 | SLC6A2 (0.33) | GAASLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL31616293 | 0.82 | SLC6A2 (0.32) | GAASLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL3535456 | 0.81 | GAA (0.32) | GAA | |
| SCHEMBL25173966 | 0.78 | GAA (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119604494-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| EP-3149007-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | claimed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | claimed |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARAMCEUTICALS, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-7351707-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS, INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | claimed |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-14 | — | — | US | claimed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | claimed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | claimed |
| EP-1461339-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | claimed |
| WO-2003057698-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| WO-2026103738-A1 | BRIDGED CYCLIC 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEONE PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) | 2026-05-21 | — | — | WO | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885GAA 593/4885CRBN 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.